Aurinia Pharmaceuticals Inc (AUPH) valuation
Aurinia Pharmaceuticals P/E ratio history
Aurinia Pharmaceuticals trades at 7.3 times its earnings over the last twelve months and 15.0 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $15.95 | $2.08 | 7.7 | 17.7 |
| Dec 31, 2024 | $8.98 | $0.05 | 179.6 | — |
| Dec 31, 2023 | $8.99 | -$0.54 | n/m | — |
| Dec 31, 2022 | $4.32 | -$0.76 | n/m | — |
| Dec 31, 2021 | $22.87 | -$1.41 | n/m | — |
| Dec 31, 2020 | $13.83 | -$0.87 | n/m | — |
| Dec 31, 2019 | $20.26 | -$0.95 | n/m | — |
| Dec 31, 2018 | $6.82 | -$0.62 | n/m | — |
| Dec 31, 2017 | $4.53 | -$1.12 | n/m | — |
| Dec 31, 2016 | $2.10 | -$0.66 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Aurinia Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Aurinia PharmaceuticalsAUPH | $2.14B | 7.3 | 15.0 | 6.9 |
| Recursion Pharmaceuticals Inc ClasRXRX | $2.14B | — | — | 38.9 |
| Biocryst PharmaceuticalsBCRX | $2.15B | — | 10.8 | 2.3 |
| Palvella TherapeuticsPVLA | $2.10B | — | — | — |
| ZymeworksZYME | $2.09B | — | 24.1 | 56.3 |
| Ufp TechnologiesUFPT | $2.20B | 30.7 | 25.3 | 3.5 |
| XencorXNCR | $2.21B | — | — | 21.1 |
| ImmunomeIMNM | $2.06B | — | — | — |
| Vera TherapeuticsVERA | $2.22B | — | — | — |
| Peer median | 30.7 | 24.1 | 21.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: AUPH financials · AUPH returns
No forecast, no recommendation. This page describes Aurinia Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.